Harvard Apparatus Regenerative Technology (OTC: HRGN) secured two bridge notes totaling $400,000 at an 8% fixed annual rate, providing immediate cash to sustain operations while it targets a $5 million capital raise. The financing relieves short‑term liquidity pressure but adds debt that could convert to equity, diluting existing shareholders if the qualified financing materializes.

Key Highlights

  • Harvard Apparatus secured two $200,000 bridge notes on May 8 2026 and July 16 2026, each with a fixed 8% annual interest rate.
  • The notes mature on May 8 2027 and July 16 2027 but will be repaid early if a qualified capital raise of at least $5 million is achieved.
  • Each note can be converted into equity if the company raises at least $200,000 before maturity, using the price paid by new investors.

Harvard Apparatus Regenerative Technology (OTC: HRGN) added $400,000 of bridge financing, splitting the amount into two identical notes of $200,000 each. The infusion arrives as the company seeks a capital raise of at least $5 million, a threshold that will trigger repayment of the notes. This immediate cash boost is intended to fund ongoing operations and position the firm for the upcoming equity financing.

By securing the funds at a fixed 8% annual rate, the company locks in predictable borrowing costs while preserving flexibility to repay early without penalty. The move signals a proactive approach to managing cash flow amid a challenging market environment.

$400,000 Bridge Funding Secured

The two bridge notes were executed on May 8 2026 and July 16 2026, each delivering $200,000 to the firm. Both notes bear a fixed interest charge of eight percent, calculated on a 360‑day year. The principal and accrued interest become due on the earlier of the next qualified capital raise, defined as gross proceeds of $5 million, or the respective maturity dates.

The notes also permit prepayment at any time, allowing the company to retire the debt ahead of schedule if cash conditions improve. This structure gives the firm a clear timeline for repayment while limiting interest expense should the capital raise materialize promptly.

Terms and Conversion Mechanics

Each bridge note includes an optional conversion feature that can be exercised by the lender if Harvard Apparatus raises at least $200,000 in equity before the note matures. Upon conversion, the outstanding balance, including accrued interest, would be exchanged for shares at the price paid by the new investors in the qualified financing. This mechanism offers a path to equity for the lender, potentially diluting existing shareholders but aligning lender interests with the success of the capital raise.

Default provisions cover missed payments, covenant breaches, bankruptcy, and large judgments, allowing the lender to accelerate repayment. The notes were approved by disinterested board members, underscoring governance oversight despite the related‑party nature of the transaction.

Timing and Market Context

The bridge financing arrives as the stock languishes near its lower historical bound, heightening investor focus on upcoming liquidity events. The company’s target of a $5 million raise is a substantial increase relative to its current market cap, suggesting that successful fundraising could markedly improve balance‑sheet strength. However, the need for bridge loans indicates short‑term cash constraints, which may pressure the share price until the capital infusion is secured.

Upcoming Maturity and Investor Outlook

The first bridge note reaches maturity on May 8 2027, with the second set for July 16 2027, unless an equity financing meeting the defined thresholds occurs earlier. These dates represent the nearest concrete milestones that will determine whether the notes are repaid in cash or converted into equity. Investors should monitor the company’s progress toward the $5 million capital raise, as achievement of that goal could trigger conversion and alter ownership structure.

The approaching maturities also provide a clear timeline for assessing the firm’s ability to service its debt and sustain operations.

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.